NRIX Stock Analysis: Buy, Sell, or Hold?
NRIX - Nurix Therapeutics, Inc. Common stock
$16.18
0.22 (1.38%)
▲
5d:
-4.15%
30d:
-0.74%
90d:
+0.43%
BUY
HIGH Confidence
Analysis Updated: May 13, 2026 12:00 AM ET
Earnings: Apr 14, 2026
0d
Smart Money Accumulation
NRIX is down 4.1% this week, but smart money is accumulating calls. Top strike: $20 2026-07-17 with 287 OI. Call ratio: 80% View Scanner →
Strength: 5.0/10
Get Alerted When NRIX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: NRIX shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: NRIX shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: NRIX is currently trading at $16.18, which is considered slightly low relative to its 30-day fair value range of $16.08 to $16.92.
Technical Outlook: Technically, NRIX is in a strong downtrend. The price is currently testing key support at $15.70. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $30.24 (+86.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NRIX is in a strong downtrend. The price is currently testing key support at $15.70. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $30.24 (+86.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$16.08 -
$16.92
Company Quality Score
56/100
(HOLD)
Options IV Signal
68th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
80.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 68th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 86.9% below Wall St target ($30.24)
Trading Range Analysis
30-Day Trading Range
$16.08 -
$16.92
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$2.63
(16.2%)
Support & Resistance Levels
Support Level
$15.70
Resistance Level
$17.39
Current Trend
Strong Downtrend
Technical data as of
May 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.65
Wall Street Target
$30.24
(+86.9%)
Revenue Growth (YoY)
-66.1%
Share & Embed Analysis
Last updated: May 14, 2026 10:42 AM ET
Data refreshes hourly during market hours. Next update: 11:42 AM
Data refreshes hourly during market hours. Next update: 11:42 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NRIX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Gwenn Hansen
SELL
4895 shares
2026-01-30
Houte Hans Van
SELL
3661 shares
2026-01-30
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 63 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$104 | 59 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
BHVN
Biohaven Pharmaceutical … |
STRONG BUY
16 analysts |
$22 | 57 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$127 | 59 HOLD |
